Effectiveness of a 6-Month 22.5-mg Leuprolide Acetate Depot Formulation With Tamoxifen for Postoperative Premenopausal Estrogen Suppression in Hormone Receptor-Positive Breast Cancer

BACKGROUND: In patients with hormone receptor-positive (HR+)/premenopausal breast cancer, luteinizing hormone-releasing hormone analogs (LHRHas) are used as standard endocrine treatment. Based on previous clinical studies, 1-month formulations are recommended in most breast cancer treatment guidelin...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Zhen-Yu, Lee, Young-jin, Kim, Heejeong, Lee, Jongwon, Chung, Il Yong, Kim, Jisun, Lee, Saebyeol, Son, Byung-Ho, Kim, Sung-Bae, Jeong, Jae Ho, Gong, Gyungyub, Ahn, Sei-Hyun, Ko, BeomSeok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113853/
https://www.ncbi.nlm.nih.gov/pubmed/33996592
http://dx.doi.org/10.3389/fonc.2021.665426

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113853/
https://www.ncbi.nlm.nih.gov/pubmed/33996592
http://dx.doi.org/10.3389/fonc.2021.665426

Ejemplares similares